CD7 and acute lymphoblastic leukemia: In the first-in-human clinical trial (NCT04004637) of CD7-redirected CAR-Ts, researchers used CD7-specific nanobodies as the targeting domain of CAR-Ts and investigated these cells in patients with CD7+ R/R T-ALL/T-cell lymphoblastic lymphoma (T-LBL) [61].